Systematic review confirms SGLT2 inhibitors and GLP-1 receptor agonists offer renal and cardiovascular benefits in type 2 diabetes with chronic kidney disease.
Background
Managing type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) presents a significant challenge, as many traditional antidiabetic drugs require dose adjustments or carry increased risks of adverse events like hypoglycemia or lactic acidosis as renal function declines. There's a critical need for therapies that not only achieve glycemic control but also offer renal protective and cardiovascular benefits, without exacerbating kidney dysfunction. This review addresses the gap by evaluating the efficacy and safety of various oral antidiabetic drugs in this vulnerable population.
Study Design
Researchers conducted a systematic review of studies published from January 2023 to September 2024, focusing on oral antidiabetic drugs for individuals with diabetes and CKD. The search included online databases, and studies reporting outcomes such as glycemic control (HbA1c), renal function (GFR, albuminuria), and adverse events were included. A risk-of-bias assessment was performed to evaluate the quality of the included studies. A total of 21 studies met the predefined inclusion criteria for this comprehensive analysis.
Results
The systematic review of 21 studies highlighted distinct efficacy and safety profiles for various oral antidiabetic drugs in CKD patients.
SGLT2 inhibitors and GLP-1 receptor agonists consistently demonstrated significant renal protective benefits, alongside their established cardiovascular advantages. SGLT2 inhibitors were noted to be particularly effective in the early stages of CKD. DPP-4 inhibitors proved safe across various CKD stages, requiring minimal dose adjustments, making them a flexible option. While Metformin remains a popular choice for glycemic control, the evidence suggests careful monitoring and potential discontinuation in advanced CKD stages due to the elevated risk of lactic acidosis. Conversely, sulfonylureas were frequently associated with an increased risk of hypoglycemia.
Key Findings
- SGLT2 inhibitors and GLP-1 receptor agonists provide renal protective and cardiovascular benefits in T2DM with CKD.
- SGLT2 inhibitors are more effective in early stages of CKD.
- DPP-4 inhibitors are safe across various CKD stages with minimal dose adjustments.
- Metformin requires monitoring and potential discontinuation in advanced CKD due to lactic acidosis risk.
- Sulfonylureas are associated with an increased risk of hypoglycemia.
Why It Matters
This systematic review provides crucial guidance for clinicians and individuals managing type 2 diabetes with CKD, emphasizing a shift towards therapies offering dual benefits. Individualized therapy is paramount, considering the patient's CKD stage, comorbid conditions, and hypoglycemia risk. The findings strongly support prioritizing SGLT2 inhibitors and GLP-1 receptor agonists for their robust renal and cardiovascular protective effects, especially in earlier CKD stages. This suggests that current protocols should increasingly integrate these drug classes to maximize patient outcomes. Regular monitoring of HbA1c, GFR, and albuminuria is reinforced as essential for optimizing treatment and minimizing adverse events.
type-2-diabetes
chronic-kidney-disease
sglt2-inhibitor
glp-1-agonist
dpp-4-inhibitor
metformin